Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided versus fixed 3-year adjuvant icotinib after resection for EGFR-mutant stage III non-squamous NSCLC
ChiCTR2200061108Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of icotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Time to discontinuation. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200061108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061108.